Minerva Neurosciences, Inc.

NERVSEC EDGAR

Pharmaceutical Preparations(MA)CIK: 1598646

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	$0.00	$0.00	$0.00	$0.00
Research and Development Expense	$11.9M	$12.7M	$14.6M	$32.0M	$22.0M
Operating Expenses	$21.8M	$23.1M	$25.2M	$45.4M	$39.3M
Operating Income (Loss)	-$21.8M	-$23.1M	-$25.2M	-$45.4M	$1.8M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	-$51.7M	$1.9M
Income Tax Expense (Benefit)	—	—	—	-$1.8M	-$1.8M
Net Income (Loss) Attributable to Parent	$1.4M	-$30.0M	-$32.1M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$37.1M	$56.9M	$55.1M	$77.1M	$57.6M
Assets, Current	$22.3M	$42.0M	$40.2M	$62.2M	$27.4M
Cash and Cash Equivalents, at Carrying Value	$21.4M	$40.9M	$36.1M	$60.8M	$25.4M
Liabilities	$62.8M	$85.4M	$75.1M	$69.1M	$5.0M
Liabilities, Current	$2.8M	$3.3M	$1.4M	$2.8M	$3.2M
Accounts Payable, Current	$1.6M	$1.8M	$969.7K	$1.9M	$995.6K
Stockholders' Equity Attributable to Parent	-$28.5M	-$20.0M	$8.0M	$52.7M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$19.6M	-$14.8M	-$24.6M	-$24.6M	-$33.8M
Net Cash Provided by (Used in) Investing Activities	$0.00	$0.00	-$16.3K	-$16.3K	$24.5M
Net Cash Provided by (Used in) Financing Activities	$74.5M	$19.6M	-$5.00	$60.0M	$13.2M
Payments to Acquire Property, Plant, and Equipment	—	—	$16.3K	$16.3K	—
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)